MTOR and acute myeloid leukemia: We have further demonstrated impaired polysome formation in AML cells treated with the mTOR inhibitor and PIM inhibitor and reduction of polysome formation of the oncoprotein cyclinD1, possibly through suppression of the HSF pathway.